Meropenem Fresenius Kabi

Meropenem, the active ingredient in Meropenem Fresenius Kabi, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired and ventilator‑associated pneumonia, and is used in patients with severe sepsis or septic shock.

GNH USA supplies Meropenem Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious infections caused by susceptible bacteria.

- Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure in patients with intra‑abdominal sepsis. - Complicated urinary tract infections: eliminates uropathogens and resolves infection in the urinary system. - Hospital‑acquired pneumonia: achieves microbiological clearance and improves respiratory outcomes. - Ventilator‑associated pneumonia: targets resistant organisms and supports recovery in ventilated patients. - Severe sepsis and septic shock: offers rapid bactericidal activity to control systemic infection.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional post‑infusion emesis. - Headache: transient cranial discomfort. - Infusion site reactions: erythema or phlebitis at the injection site. - Rash: mild cutaneous eruption.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or high doses. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption. - Anaphylaxis: acute hypersensitivity requiring immediate discontinuation. - Renal impairment: worsening kidney function in susceptible individuals. - Hepatic enzyme elevation: transient increase in liver transaminases. - Neutropenia: reduced white blood cell count, increasing infection risk.

Careful assessment and monitoring are required before and during therapy. - Renal function: adjust dose in patients with impaired clearance. - Hepatic function: monitor liver enzymes during prolonged treatment. - Allergic reactions: discontinue if signs of hypersensitivity appear. - Valproic acid co‑administration: increased risk of seizures; avoid combination. - Neonates and infants: higher seizure susceptibility; use with caution. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: concurrent use can precipitate seizures. - Probenecid: may increase meropenem plasma concentrations, raising toxicity risk. - Carbapenem‑induced reduction of oral contraceptives: may decrease contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Aminoglycosides: watch for additive nephrotoxicity. - Anticoagulants (e.g., warfarin): observe coagulation parameters for potential changes.